A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer

Natalia J. Gurule(University of Colorado Anschutz Medical Campus), Lynn E. Heasley(University of Colorado Health)
npj Precision Oncology
May 17, 2021
10.1038/s41698-021-00181-4
Cited by 40

Related Papers

A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
|Oncogenesis|2013|256
Rapidly Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in NSCLC Cell Lines through De-Repression of FGFR2 and FGFR3 Expression
|PLoS ONE|2010|145
Differential Gene Regulation by Specific Gain-of-function JNK1 Proteins Expressed in Swiss 3T3 Fibroblasts
|Journal of Biological Chemistry|2002|48
A Receptor Tyrosine Kinase Network Composed of Fibroblast Growth Factor Receptors, Epidermal Growth Factor Receptor, v-erb-b2 Erythroblastic Leukemia Viral Oncogene Homolog 2, and Hepatocyte Growth Factor Receptor Drives Growth and Survival of Head and Neck Squamous Carcinoma Cell Lines
|Molecular Pharmacology|2013|43
TP53 Null Mutations Identify Lung Cancer Cell Lines with Highest Sensitivity to the Nontaxane Microtubule Inhibitor Eribulin
|Molecular Pharmacology|2021|15